On the other hand, targeting epidermal growth factor (EGFR) in lung cancer leads to generalized cutaneous toxicity and cardiotoxicity in the treatment of HER2-positive breast cancer using trastuzumab [26,27]. Here, ERBB2 is linked to breast carcinoma.